Azacitidine Does Not Impact Prognosis in Intermediate-Risk Myelodysplastic Syndromes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Cancer Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Refinement of Prognosis and the Effect of Azacitidine in Intermediate-Risk Myelodysplastic Syndromes
Blood Cancer J 2021 Feb 11;11(2)30, K Liapis, V Papadopoulos, G Vrachiolias, AG Galanopoulos, M Papoutselis, SG Papageorgiou, PT Diamantopoulos, V Pappa, NA Viniou, A Kourakli, D Τsokanas, TP Vassilakopoulos, E Hatzimichael, E Bouronikou, M Ximeri, C Pontikoglou, A Megalakaki, P Zikos, P Panayiotidis, M Dimou, S Karakatsanis, M Papaioannou, A Vardi, F Kontopidou, N Harchalakis, I Adamopoulos, A Symeonidis, I KotsianidisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.